Valuation: Imugene Limited

Market Cap 19.1M 13.33M 11.9M 11.07M 10.07M 19.02M 1.29B 133M 52.22M 658M 50.05M 48.96M 2.11B P/E 2027 *
-0.7x
P/E 2028 * -1.01x
Enterprise Value 10.3M 7.19M 6.42M 5.97M 5.43M 10.25M 696M 71.87M 28.16M 355M 26.99M 26.4M 1.14B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
96.9%
Yield 2027 *
-
Yield 2028 * -
1 day-7.14%
1 week+5.41%
Current month-7.14%
1 month-32.76%
3 months-62.86%
6 months-72.14%
Current year-89.32%
1 week 0.04
Extreme 0.039
0.05
1 month 0.04
Extreme 0.037
0.06
Current year 0.04
Extreme 0.037
0.41
1 year 0.04
Extreme 0.037
0.43
3 years 0.04
Extreme 0.037
5.1
5 years 0.04
Extreme 0.037
21.25
10 years 0.04
Extreme 0.037
21.25
Manager TitleAgeSince
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/06/2022
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member 66 23/04/2019
Director/Board Member 61 07/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
12/19/25 A Free

Director

29,411 0.0093%
12/19/25 A Free

Director

14,706 0.0047%
12/19/25 A Free

Director

29,411 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%+5.41%-90.60%-97.71% 13.33M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.03%-1.85%+35.60%+90.11% 37.66B
Weighted average by Cap. +0.56%-2.94%+51.34%+115.56%

Financials

2027 *2028 *
Net sales - -
Net income -36.17M -25.24M -22.54M -20.97M -19.07M -36.01M -2.44B -252M -98.88M -1.25B -94.78M -92.71M -4B -28.65M -19.99M -17.86M -16.61M -15.11M -28.53M -1.93B -200M -78.33M -986M -75.08M -73.44M -3.17B
Net Debt -8.8M -6.14M -5.48M -5.1M -4.64M -8.76M -594M -61.4M -24.06M -303M -23.06M -22.56M -972M 8.5M 5.93M 5.3M 4.93M 4.48M 8.46M 574M 59.31M 23.24M 293M 22.27M 21.79M 939M
Projected Income Statement - Annual - Imugene Limited
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
14
Date Price Change Volume
09/10/26 A$0.0390 -7.14% 1,833,594
08/10/26 A$0.0420 +2.44% 2,315,349
07/10/26 A$0.0410 0.00% 4,284,215
06/10/26 A$0.0410 -4.65% 3,986,611
05/10/26 A$0.0430 +16.22% 19,537,971
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Imugene Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0390AUD
Average target price
0.2300AUD
Spread / Average Target
+489.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Imugene Limited